



Biotech Daily

Friday November 27, 2015

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH DOWN: MESOBLAST UP 15.5%; POLYNOVO DOWN 9%**
- * **CLARIFICATION: TISSUE THERAPIES, THE ASX AND CHI-X TRADING**
- * **ONCOSIL RECEIVES \$1.5m FEDERAL R&D TAX REFUND**
- * **STIRLING TO BACK-DOOR MX360 FOR NON-BIOTECH WEB-TRADING**
- * **M&G GROUP INCREASE, DILUTED TO 10.3% OF MESOBLAST**
- * **VIBURNUM, WYLLIE FUNDS TAKE 9.4% OF UNIVERSAL BIOSENSORS**
- * **MEDIBIO 'SURPRISED' BY RUSH FOR CORPORATE STRESS TEST PILOT**

MARKET REPORT

The Australian stock market slipped 0.16 percent on Friday November 27, 2015 with the ASX200 down 8.1 points to 5,202.6 points. Eleven of the Biotech Daily Top 40 stocks were up, 15 fell, 11 traded unchanged and three were untraded.

Mesoblast was the best, recovering a further 24 cents or 15.5 percent to \$1.79 with 2.9 million shares traded, followed by Antisense up 11.4 percent to 7.8 cents with 644,419 shares traded.

Admedus climbed five percent; Neuren improved 4.05 percent; Avita, Compumedics and Prana were up more than three percent; Anteo, Ellex, Reva and Universal Biosensors were up more than one percent; with Resmed up 0.1 percent.

Highlighting the ASX and Chi-X data issue (see clarification below) Commsec Iress reports Tissue Therapies led the falls again, but this is inaccurate and will be resolved. Polynovo led the falls down 1.5 cents or 8.8 percent to 15.5 cents with 774,432 shares traded, followed by Viralytics down 8.45 percent to 65 cents with 171,731 shares traded.

Atcor lost 7.9 percent; Benitec, Genetic Technologies, Medical Developments, Orthocell and Starpharma were three percent or more; Oncosil, Pro Medicus and Tissue Therapies shed more than two percent; Clinuvel, Impedimed and Nanosonics were down more than one percent; with Cochlear, CSL and Sirtex down by less than one percent.

CLARIFICATION: TISSUE THERAPIES

Last night's edition reported that: "Tissue Therapies led the falls, down 0.6 cents or 12.5 percent to 4.2 cents with 10,655 shares traded."

Tissue Therapies director Dr Christian Behrenbruch told Biotech Daily that, on the ASX, the company fell one cent or 2.1 percent from 4.8 cents to 4.7 cents.

According to the Commonwealth Securities (Commsec) website, reporting ASX data, this was correct, with 655 shares traded.

However, Biotech Daily uses Commsec Iress to report final prices and compile the daily market report, and Iress reports both ASX data and the Chi-X trading platform.

Yesterday, Tissue Therapies traded the 655 shares on the ASX, but there was a later trade of 10,000 shares at 4.2 cents on Chi-X.

Iress and Chi-X have told Biotech Daily that Chi-X is responsible for 20 to 25 percent of all Australian trading.

Today, according to Iress, with the last trade on the ASX, Tissue Therapies fell 0.6 cents or 12.8 percent to 4.1 cents with 194,119 shares traded.

Biotech Daily is considering how to deal with the conflicting information from Iress.

ONCOSIL MEDICAL

Oncosil says it has received \$1,535,444 from the Australian Tax Office under the Federal Government Research and Development Tax Incentive program.

Oncosil said that the cash rebate was related to expenditure on eligible Australian and international research and development activities conducted in the year to June 30, 2015.

Oncosil fell half a cent or 2.9 percent to 17 cents with 1.6 million shares traded.

STIRLING PRODUCTS

Stirling says it will acquire all of the issued capital of an internet trading platform Mx360 Group Pty Ltd for 80,000,000 Stirling shares at a deemed price of 10 cents a share.

Stirling has previously told Biotech Daily that when the acquisition was completed it would no longer have an involvement in biotechnology (BD: Sep 18, 2015).

In 2011, Stirling was placed in administration having failed to commercialize the Kiev, Ukraine- acquired Immunoxel for AIDS, tuberculosis, kidney disease and H1N1 influenza, or 'swine' influenza (BD: Jul 26, 2011; Aug 6, 2015).

In 2009, Stirling claimed 100 percent efficacy for drug-resistant tuberculosis with the Immunoxel natural product citing a 12-patient Kiev, Ukraine trial (BD: Apr 16, 2009).

Stirling managing director and former Victoria Police officer Peter Boonen told Biotech Daily his company was involved in the commercialization of Immunoxel and the intellectual property was owned by the Kiev-based Ekomed.

Stirling was suspended at 0.2 cents, or \$4.00, following the 2,000-to-one consolidation.

MESOBLAST

M&G Investment Funds have increased their substantial holding in Mesoblast from 32,018,195 shares (11.25%) to 39,157,613 shares but were diluted to 10.30 percent.

M&G said that it bought 1,497,235 American depository shares, equivalent to 7,486,175 Australian shares in the recent US capital raising (BD: Nov 16, 2015).

M&G said it had bought and sold Mesoblast shares between February 28, 2012 and November 19, 2015 at a range of prices, with the single largest trade, on March 6, 2013, the sale of 167,019 shares for \$1,052,220 or \$6.30 a share.

Mesoblast climbed 24 cents or 15.5 percent to \$1.79 with 2.9 million shares traded.

UNIVERSAL BIOSENSORS

The Perth, Western Australia-based Viburnum Funds says it has become a substantial shareholder in Universal Biosensors with 16,431,603 Chess depository interests (9.36%). The Viburnum substantial shareholder notice said that the holders included Wyllie Funds Management, Wyllie Group and Rhonda Wyllie along with JP Morgan as a registered holder.

Viburnum said that between August 27 and November 25, 2015, the funds acquired 11,434,451 shares for \$4,886,111 or 42.7 cents a share

Universal Biosensors was up half a cent or 1.05 percent to 48 cents.

MEDIBIO

Medibio says a planned 50-patient pilot corporate stress test program has received pre-registrations for 100 participants and will be capped at that number.

In September, Medibio launched its “corporate wellness partner program” with an agreement to provide its cardiac corporate stress product to the Perth Western Australia-based “mental wellness” provider Vital Conversations, which describes its staff as psychologists and coaches and says it specializes in psychology, coaching, organisational development, profiling and leadership (BD: Sep 25, Nov 6, 2015).

Medibio said that its cardiac rhythm-based corporate stress product was “the first objective test to measure the level of stress and its impact on health and wellbeing” and included a series of mobile telephone application-based intervention or treatment modules “tailored specifically for the employee’s stress level”.

Today Medibio said that Vital Conversations’ first customer for the corporate stress test was an unnamed “a leading international professional services company with in excess of 5,000 employees in Australia and 200,000 worldwide”.

Medibio said that the rapid uptake “surprised both Vital and the customer corporation and provides the first indication of potential demand and uptake for Medibio’s stress test”.

The company said that Vital Conversations indicated it had strong interest from other potential customers.

Medibio said that it would data analytics and reporting on a per test basis to Vital Conversations, its customer and their employees with net revenue to Medibio between \$40 and \$60 per staff member per test.

Medibio fell two cents or 5.9 percent to 32 cents.